Biased agonism has been proposed as a means to separate desirable and adverse drug responses downstream of G protein-coupled receptor (GPCR) targets. Herein, we describe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferentially activate receptors to couple to G proteins or to recruit βarrestin proteins. By comparing relative bias for MOR-mediated signaling in each pathway, we demonstrate a strong correlation between the respiratory suppression/antinociception therapeutic window in a series of compounds spanning a wide range of signaling bias. We find that βarrestin-biased compounds, such as fentanyl, are more likely to induce respiratory suppression at weak analgesic doses, while G protein signaling bias broadens the therapeutic window, allowing for antinociception in the absence of respiratory suppression. Exploiting ligand bias enables the design of new opioid receptor ligands aimed at reducing side effects.
CITATION STYLE
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., … Bohn, L. M. (2017). Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell, 171(5), 1165.e13-1175.e13. https://doi.org/10.1016/j.cell.2017.10.035
Mendeley helps you to discover research relevant for your work.